Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGüldan, Mustafa
dc.contributor.authorUnlu, Selen
dc.contributor.authorAbdel-Rahman, Sama
dc.contributor.authorÖzbek, Laşin
dc.contributor.authorGaipov, Abduzhappar
dc.contributor.authorCovic, Andreea
dc.contributor.authorSoler, María José
dc.date.accessioned2024-10-21T07:02:26Z
dc.date.available2024-10-21T07:02:26Z
dc.date.issued2024-07-25
dc.identifier.citationGuldan M, Unlu S, Abdel-Rahman SM, Ozbek L, Gaipov A, Covic A, et al. Understanding the Role of Sex Hormones in Cardiovascular Kidney Metabolic Syndrome: Toward Personalized Therapeutic Approaches. J Clin Med. 2024 Jul 25;13(15):4354.
dc.identifier.issn2077-0383
dc.identifier.urihttps://hdl.handle.net/11351/12084
dc.descriptionCardiovascular kidney metabolic syndrome; Chronic kidney disease; Sex hormone
dc.description.abstractCardiovascular kidney metabolic (CKM) syndrome represents a complex interplay of cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic comorbidities, posing a significant public health challenge. Gender exerts a critical influence on CKM syndrome, affecting the disease severity and onset through intricate interactions involving sex hormones and key physiological pathways such as the renin–angiotensin system, oxidative stress, inflammation, vascular disease and insulin resistance. It is widely known that beyond the contribution of traditional risk factors, men and women exhibit significant differences in CKM syndrome and its components, with distinct patterns observed in premenopausal women and postmenopausal women compared to men. Despite women generally experiencing a lower incidence of CVD, their outcomes following cardiovascular events are often worse compared to men. The disparities also extend to the treatment approaches for kidney failure, with a higher prevalence of dialysis among men despite women exhibiting higher rates of CKD. The impact of endogenous sex hormones, the correlations between CKM and its components, as well as the long-term effects of treatment modalities using sex hormones, including hormone replacement therapies and gender-affirming therapies, have drawn attention to this topic. Current research on CKM syndrome is hindered by the scarcity of large-scale studies and insufficient integration of gender-specific considerations into treatment strategies. The underlying mechanisms driving the gender disparities in the pathogenesis of CKM syndrome, including the roles of estrogen, progesterone and testosterone derivatives, remain poorly understood, thus limiting their application in personalized therapeutic interventions. This review synthesizes existing knowledge to clarify the intricate relationship between sex hormones, gender disparities, and the progression of CVD within CKM syndrome. By addressing these knowledge gaps, this study aims to guide future research efforts and promote tailored approaches for effectively managing CKD syndrome.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesJournal of Clinical Medicine;13(15)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectSíndrome metabòlica - Tractament
dc.subjectInsuficiència renal crònica - Tractament
dc.subjectSistema cardiovascular - Malalties - Tractament
dc.subjectHormones sexuals
dc.subjectDiferències entre sexes
dc.subject.meshMetabolic Syndrome
dc.subject.mesh/therapy
dc.subject.meshGonadal Steroid Hormones
dc.subject.meshCardio-Renal Syndrome
dc.subject.meshSex Characteristics
dc.titleUnderstanding the Role of Sex Hormones in Cardiovascular Kidney Metabolic Syndrome: Toward Personalized Therapeutic Approaches
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/jcm13154354
dc.subject.decssíndrome metabólico
dc.subject.decs/terapia
dc.subject.decshormonas esteroides gonadales
dc.subject.decssíndrome cardiorrenal
dc.subject.decscaracterísticas sexuales
dc.relation.publishversionhttps://doi.org/10.3390/jcm13154354
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Guldan M, Unlu S, Abdel-Rahman SM, Ozbek L] Department of Medicine, Koç University School of Medicine, Istanbul, Turkey. [Gaipov A] Department of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan. [Covic A] Department of Nephrology, Grigore T. Popa University of Medicine, Iasi, Romania. [Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Referencia en Enfermedad, Glomerular Compleja del Sistema Nacional de Salud de España (CSUR), RICORS2040 (Kidney Disease), Barcelona, Spain. GEENDIAB (Grupo Español de Estudio de la Nefropatía Diabética), Santander, Spain
dc.identifier.pmid39124622
dc.identifier.wos001287015300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record